When urinary changes do occur, they are more likely related to indirect factors associated with the medication's primary effects rather than a direct pharmacological action on the urinary system
Migration of V1 and V2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat
or collapse (possible anaphylaxis) Severe abdominal pain (possible pancreatitis) Signs of infection at the injection site (redness, swelling, discharge, or fever) Persistent vomiting or inability to tolerate fluids Chest pain, palpitations, or difficulty breathing Severe dizziness or loss of consciousness For non-urgent concerns, contact your GP or call NHS 111 for advice
Learning Objectives Relate pharmacodynamic and pharmacokinetic properties of GLP-1As when used for eating disorders
Agenda Co-chairs Dr Luz de Regil Director, Department of Nutrition and Food Safety, WHO and Dr Kirsten Bibbins Domingo Editor-in-Chief, JAMA Moderator Dr Gaya Manori Gamhewage, Director, Department of Communication, WHO Welcoming Dr Luz De Regil Director NFS, WHO and Dr Kirsten Bibbins-Domingo, Editor-in-Chief, JAMA Presentation: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults Dr Francesca Celletti, Senior Advisor Obesity, Department of Nutrition and Food Safety, WHO and Dr
